Bookmark
Forward
QuickView for enfuvirtide (compound)
PubChem Substance
| Name: | enfuvirtide |
|---|---|
| PubChem Substance ID: | 17396673 |
| Synonyms: |
Enfuvirtide (USAN); Fuzeon (TN); Enfuvirtide; Fuzeon; 159519-65-0; D02499
|
DrugBank
Identification
| Name: | enfuvirtide |
|---|---|
| Name (isomeric): | DB00109 |
| Drug Type: | biotech |
| Synonyms: |
Envelope polyprotein GP160 precursor [Contains: Exterior membrane glycoprotein,GP120, Transmembrane glycoprotein,GP41]
|
| Brand: | Fuzeon (Roche Pharmaceuticals), Fuzeon |
| Category: | Anti-HIV Agents, HIV Fusion Inhibitors |
| CAS number: | 159519-65-0 |
Pharmacology
| Indication: | Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS. |
|---|---|
| Mechanism of Action: |
Enfuvirtide binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. It works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming i...
show more » |
| Protein binding: | 92% |
| Half Life: | 3.8 +/- 0.6 hrs |
| Clearance: | 24.8 +/- 4.1 mL/h/kg [HIV-1 infected adult and pediatric subjects following a 90-mg single SC dose of enfuvirtide] 30.6 +/- 10.6 mL/h/kg [Following 90-mg twice daily dosing of FUZEON SC in combination with other antiretroviral agents in HIV-1 infected subjects] 40 +/- 17 mL/h/kg [pediatric patients in the presence of concomitant medications including antiretroviral agents receiving the 2 mg/kg twice daily dose] |
| Affected organisms: | Human Immunodeficiency Virus |
Targets
